<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01573117</url>
  </required_header>
  <id_info>
    <org_study_id>iCOOL 1</org_study_id>
    <nct_id>NCT01573117</nct_id>
  </id_info>
  <brief_title>A Randomized Trial Comparing 2 Methods for Rapid Induction of Cooling in Stroke Patients, Cold Infusions vs. RhinoChill (iCOOL 1)</brief_title>
  <acronym>iCOOL 1</acronym>
  <official_title>iCOOL 1 (Induction of COOLing 1): A Randomized Trial Comparing 2 Methods for Rapid Induction of Cooling in Stroke Patients, Cold Infusions vs. RhinoChill</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mild hypothermia improves outcome in patients with global cerebral ischemia after cardiac
      arrest. Hypothermia seems promising also in other acute hypoxic-ischemic or in brain swelling
      associated cerebrovascular disease. The narrow-time-frame is a major issue (&quot;time is brain&quot;).
      To provide immediate cooling without delay, easy to use, mobile and effective methods are
      needed. Cold infusions (4 °C) are an accepted standard worldwide. The RhinoChill (BeneChill,
      USA) is a new device. A comparison of these two induction methods has never been done before.
      Neither was the effect of cold infusions on brain-temperature measured. For the first time
      iCOOL 1 compares feasibility, safety and efficacy of the two methods.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brain temperature</measure>
    <time_frame>-15 to +60min</time_frame>
    <description>Primary endpoint: Change of brain temperature during one hour after start of cooling. Repeated measurement ANOVA for within subject contrasts (phase 1 (0 to 15min), 2 (15 to 30min), 3 (30 to 45min) and 4 (45 to 60min)) vs. baseline (-15 to 0min)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>(Neuro-)vital parameters</measure>
    <time_frame>-15 to +60 min</time_frame>
    <description>Effects on (neuro-)vital parameters (e.g. HR, AP, ICP, CPP) are registered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral autoregulation</measure>
    <time_frame>-15 to +60 min</time_frame>
    <description>Cerebral auto-regulation parameters (e.g. PRx) are calculated on the basis of the (neuro-)vital parameters monitored.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>0-6 months</time_frame>
    <description>Various safety parameters, such as bleeding complications, cardiac decompensation, or local irritations in the nasopharynx are assessed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Ischemic Stroke</condition>
  <condition>Hemorrhagic Stroke</condition>
  <arm_group>
    <arm_group_label>Cold infusions</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infusion of 2L cold crystalloid solution (4°C) over 30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RhinoChill</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nasopharyngeal cooling with the RhinoChill device (BeneChill, USA)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RhinoChill</intervention_name>
    <description>Nasopharyngeal cooling with the RhinoChill device</description>
    <arm_group_label>RhinoChill</arm_group_label>
    <other_name>BeneChill, USA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cold crystalloid infusions, 0.9%NaCl or Ringer's solution</intervention_name>
    <description>Infusion of 2L cold crystalloid solution (4°C) over 30 minutes</description>
    <arm_group_label>Cold infusions</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sedation, intubation and mechanical ventilation

          -  Combined ICP-temperature-probe

          -  Indication to lower body temperature

          -  Age ≥ 18 years

        Exclusion Criteria:

          -  Body weight &gt; 120 kg

          -  Fever &gt; 38.5°C

          -  Chronic sinusitis

          -  Current or past fracture or surgery of the paranasal sinuses

          -  Severe infection with bacteremia or sepsis ≤ 72 h

          -  Severe renal insufficiency

          -  Severe liver insufficiency

          -  Acute pulmonary embolism

          -  Acute myocardial infarction

          -  Severe cardiac insufficiency (NYHA ≥ III)

          -  Threatening ventricular dysrhythmia

          -  Cardiac dysrhythmia with bradycardia (heart rate &lt; 50 /min, QTc &gt; 450 ms, sick sinus
             syndrome, AV-block II-III°).

          -  Known hematologic disease with increased risk of thrombosis (e.g. cryoglobulinemia,
             cold agglutinins, sickle cell anemia)

          -  Known vasospastic vascular disorder (e.g. Raynaud's phenomenon or thromboangiitis
             obliterans)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sven Poli, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Heidelberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neuro Intensive Care Unit 2, Dept. of Neurology, University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2012</study_first_submitted>
  <study_first_submitted_qc>April 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2012</study_first_posted>
  <last_update_submitted>April 25, 2012</last_update_submitted>
  <last_update_submitted_qc>April 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Heidelberg</investigator_affiliation>
    <investigator_full_name>Dr. Sven Poli</investigator_full_name>
    <investigator_title>Consultant Neurologist, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>hypothermia</keyword>
  <keyword>induction of hypothermia</keyword>
  <keyword>cold infusion</keyword>
  <keyword>nasopharyngeal cooling</keyword>
  <keyword>stroke</keyword>
  <keyword>intracranial hemorrhage</keyword>
  <keyword>cerebrovascular disease</keyword>
  <keyword>neuro intensive care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

